Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biogaia Adr Class B BIOGY

Healthcare Biotechnology
Biogaia AB is a Sweden-based healthcare company that is engaged in the development and sell of probiotic products. The Company develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics... see more

Recent & Breaking News (PINL:BIOGY)

Alnylam Files Clinical Trial Application to Initiate a Phase 1 Study for ALN-AS1, a Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase-1 (ALAS-1) for the Treatment of Hepatic Porphyrias

Business Wire January 5, 2015

Onco360 Chosen by Bayer as Limited Distribution Pharmacy Provider

Business Wire January 5, 2015

Bristol-Myers Squibb and California Institute for Biomedical Research (Calibr) Sign Worldwide Research Collaboration and License Agreement Focused on New Treatment Approaches for Fibrotic Diseases

Business Wire January 5, 2015

Aduro Biotech Closes $51.4 Million Series D Financing

Business Wire January 5, 2015

CytomX Expands Leadership Team with Addition of Michael Kavanaugh, M.D., as Chief Scientific Officer and Head of Research and Early Development

PR Newswire January 5, 2015

Cancer Genetics, Inc. Receives Approval to Provide Oncology Testing for Patients in California

GlobeNewswire January 5, 2015

Cancer Genetics, Inc. Receives Approval to Provide Oncology Testing for Patients in California

GlobeNewswire January 5, 2015

Cerus Reports EU Phase 3 Clinical Trial of INTERCEPT Red Blood Cells Met Primary Endpoint

Business Wire January 5, 2015

Global Blood Therapeutics to Present at Upcoming Investor Conferences

Marketwired January 5, 2015

Advaxis Submits Investigational New Drug Application to FDA for ADXS-HER2

GlobeNewswire January 5, 2015

Pacific Biosciences Customers Present Work on Complex De Novo Genomes and Genome Annotation at the International Plant & Animal Genome XXIII Conference

GlobeNewswire January 5, 2015

Pfizer Acquires Redvax GmbH

Business Wire January 5, 2015

Navidea Strengthens Leadership Team to Accelerate Lymphoseek® Growth

Business Wire January 5, 2015

Compugen Discloses Initial Experimental Results for Predicted Antibody Drug Conjugate Targets

Business Wire January 5, 2015

BioCryst Pharmaceuticals Announces the Appointment of Lynne Powell as Chief Commercial Officer

GlobeNewswire January 5, 2015

RXi Pharmaceuticals to Present at the 7th Annual Biotech Showcase(TM)

PR Newswire January 5, 2015

Conatus to Report Top-line Results From ACLF and Organ Impairment Clinical Trials of Emricasan

GlobeNewswire January 5, 2015

RedHill Biopharma Business Outlook and Anticipated Key Milestones for 2015

GlobeNewswire January 5, 2015

Cellceutix Releases Confidence Interval Statistics Showing Clinical Success Rates for Brilacidin in Treatment of ABSSSI

Marketwired January 5, 2015

Celator® Pharmaceuticals Receives $1,937,000 from New Jersey's Technology Business Tax Certificate Transfer Program

PR Newswire January 5, 2015